Jayr Schmidt Filho

Hematologist - specialized in blood malignancies and hematopoietic stem cell transplant, Head of hematology department at A.C.Camargo Cancer Center

[ScienceLink @sciencelinkonco]

#HematoTime
Dr. Jayr Schmidt Filho (@jayrsf_)

https://t.co/Snr2jxQV1N

[Americas Health Foundation (AHF) @AmeriHealthFoun]

Advanced therapies like CAR T-cell treatment require coordination across clinicians, regulators, patient advocates, and health system stakeholders.

Our new paper in Frontiers in Hematology explores the challenges and opportunities for equitable CAR T-cell therapy access +

[Blood Journals Portfolio @BloodPortfolio]

Tailored infectious screening, including endemic pathogens, is critical in CAR-T candidates in endemic areas. Read in Blood Global Hematology: https://t.co/CXAE12d9iK #CARTCell #BloodGlobal

[SBTMO @SBTMO]

O Dr. Jayr Schmidt Filho (A.C.Camargo Cancer center), um dos palestrantes do V Multirregional SBTMO 2026, convida a todos para participarem do nosso Encontro de Prevenção e Tratamento de Recaídas pós TCTH, que ocorrerá na próxima semana, dia 13 de março! https://t.co/P8EMVWEUd9

[Jayr Schmidt Filho @jayrsf_]

@hhashmi87 @bhemato @Merida Glad to share this moment with you all!

[Hamza Hashmi @hhashmi87]

Great day sharing ideas, research, and debates on #myeloma with @bhemato and colleagues at MMSparks event in @merida #CureMyeloma #mmsm #MedEd #medtwitter #CART #bispecifics #MyelomaMexico #MyelomaFriends

[Luciano J Costa @End_myeloma]

Newly diagnosed with MM? MASTER-2 addressed response adapted therapy with the perspective of finite treatment. Accruing fast! #mmsm

[Jayr Schmidt Filho @jayrsf_]

Great session at Brazilian Lymphoma Conference (BLC) 2025 from @abhhoficial: traditional debate on CART vs Bispecifics, with @GuiperiniMD, and moderated by Daniel Tabak and Belinda Simoes. The panel's overall opinion is that both therapies are complementary and not antagonistic.

[Lymphoma Experience @LymphomaEx]

Necesitamos empujar el desarrollo y acceso de CAR-T en Latinoamérica.

Seguiremos empujando para avanzar.

#LEx25

[Jayr Schmidt Filho @jayrsf_]

@LymphomaEx Our pleasure!

[Jayr Schmidt Filho @jayrsf_]

Honored to participate in Lymphoma Experience (LEx), organized by @cytohance @iHematologo and @nico30f in Puerto Varas 🇨🇱
Pleasure to discuss the reality of CAR-T cell treatment in LATAM, sharing our experience through clinical cases presented by @ThaisFischer4 🩸🧬

[Jayr Schmidt Filho @jayrsf_]

@LymphClinician Glad to have you with us!

[Tycel Phillips @LymphClinician]

Had a great time debating @jayrsf_ and visiting with the great team at A.C Camargo Cancer Center earlier this week.

[Jayr Schmidt Filho @jayrsf_]

@MedulaFla Foi um prazer levar a mensagem de uma data tão importante! 🩸🧬

[EMBAIXADA FLAMEDULA OFICIAL @FlaMedula]

Dr. @jayrsf_ hematologista, transplante de medula óssea e terapia celular, líder do centro de referência de neoplasia hematológicas do AC Camargo Câncer Center, tem uma mensagem sobre o Dia Mundial do Doador de Medula Óssea!
#globaldonordrive #thankyoudonor #WMDD23 #redome30anos

[Jayr Schmidt Filho @jayrsf_]

@MedulaFla @FlaMedula 🙏🩸🧬💚

[SBTMO @SBTMO]

Amanhã, dia 03/08 (quinta-feira), às 14h, teremos a 39ª Reunião dos Gerentes de Dados da SBTMO.

Para participar, acesse no horário de início da atividade o link zoom:
https://t.co/987hqekucM
ID da reunião: 892 0245 2945
Senha de acesso: gdsbtmo

[Toby Eyre @tobyeyre82]

TRANSCEND #CLL 004
Of 137 leukapher 117->lisocel
53 (DL1=4; DL2=49) in primary efficacy ax (PAS)
median 5 lines
All BTKi exp
CR/CRi in PAS 18% ORR 43% uMRD PB 63%
mDOR 35m
PFS 12m
Responders->✅DOR
CRS 85% G3 8.5%
NE 45% G3 18%
Effective in v high risk but notable tox
#ASCO2023

[vp @vicpotter123]

Amazing ebmt, meeting old friends xx

[Jayr Schmidt Filho @jayrsf_]

@vicpotter123 Really nice to see you again @vicpotter123 !